益佰制药(600594) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a loss for the first half of 2025, with a significant narrowing of the loss compared to the same period last year, projecting net profit attributable to shareholders between -21.24 million CNY and -17.70 million CNY, based on unaudited preliminary results Key Financial Indicators Forecast | Indicator | Estimated Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -21.24 million to -17.70 million | | Net Profit After Non-Recurring Gains and Losses | -33.36 million to -27.80 million | - This performance forecast is unaudited by a certified public accountant[4] Operating Performance and Financial Status for the Same Period Last Year For comparison, the company reported a net loss of -106.49 million CNY and a non-recurring adjusted net loss of -111.54 million CNY for the first half of 2024, with basic earnings per share at -0.134 CNY Key Financial Indicators for H1 2024 | Indicator | H1 2024 Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -106.49 million | | Net Profit After Non-Recurring Gains and Losses | -111.54 million | | Earnings Per Share | -0.134 | Primary Reasons for Current Period's Expected Loss The core reason for the continued loss is a 15% projected decrease in revenue due to reduced sales of main products, yet effective cost and expense control, with an estimated 20% reduction, has narrowed the overall loss compared to the prior year - The primary reason for the expected loss is the impact of core business operations, with main product sales decreasing, leading to an estimated 15% decline in revenue[7] - Despite the revenue decline, costs and expenses decreased more significantly, with an estimated 20% reduction, resulting in a smaller loss for the current period compared to the prior year[7] Risk Warning The company emphasizes that this performance forecast is based on preliminary internal calculations and is unaudited, but confirms no significant uncertainties affect its accuracy - This performance forecast is a preliminary calculation by the company's finance department and has not yet been audited[8] - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8] Other Explanatory Matters The company reminds investors that the final accurate financial data will be based on the officially disclosed 2025 semi-annual report, and advises caution regarding investment risks - The final financial data will be subject to the company's officially disclosed 2025 semi-annual report[9]